NCT06210438View on ClinicalTrials.gov

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions

TNBCBrain Metastasis

Interventions

DRUG

SHR-A1921 + Bevacizumab

SHR-A1921 + Bevacizumab

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER